Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Item

http://www.wikidata.org/entity/Q34611626

Q34611626

about

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Reply to F. Tomao et al.Optimal systemic therapy for early breast cancer in women: a clinical practice guideline Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials.Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer.Adjuvant endocrine therapy in premenopausal women with breast cancer.Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study.News on the medical treatment of young women with early-stage HER2-negative breast cancer.Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment.Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).Should age impact breast cancer management in young women? Fine tuning of treatment guidelines.Metastatic and triple-negative breast cancer: challenges and treatment options An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

P2860

Q27002430-7F085946-DFF3-45FF-B3F3-1058D0611B96 Q28085062-44311EF4-472C-4B06-86AD-34D13E3A53A0 Q33816570-6A3D0F6E-AEF4-4899-8365-7EB5149CBE4D Q35239634-8D1648F3-2F4D-4CB8-B943-9F1978557951 Q35673773-AF2F5504-DD11-4E31-AF22-CAABAFED55D1 Q36915190-56CAF4C9-9FFF-4C0C-B0A3-4C97F713D189 Q36941307-71B3FCC3-90F9-490F-B859-9CA4F2839867 Q36976772-B553E672-9607-4286-948D-D8087C14D4B9 Q37158433-4339271E-002C-46D5-B852-CDDC2D8D7116 Q37547937-2DC19CDD-1A23-4675-A37D-B646EAB6F510 Q38547729-AB005992-D951-4DF9-A993-7CCCEF2CC02B Q38551397-7F023361-6578-45D8-8304-33F24B6EAE67 Q38648577-404896CE-0F4C-4FE3-8541-25665FEDD911 Q38658655-EA85A860-1864-4FDF-898B-097C080665F8 Q38692427-68E230BE-B4AD-40FB-9753-94C223FDD6FC Q38870541-86E1A6E7-C35F-4C6A-AB83-5DD2E8019014 Q38968531-DC65E70E-C626-4632-BDB9-264FC3655362 Q38984147-F3F217AB-8FF2-455C-BA92-FE1B959EC147 Q38992134-5A2C2C7B-EAB5-42DE-B4D2-07D98C2292E7 Q39028384-9FABBCC7-FD33-417A-9BFB-ACB71D381D35 Q39375196-491F0E7B-9568-4558-8387-1E684B83780F Q40061357-ED399BFA-6780-42DE-8446-C8E6B05235FA Q48329409-93E5ECB8-D43A-4BFC-A55F-CEFE0E247AC5 Q52709099-0A88B39C-EF50-4A2D-AB49-B2E3F97F36D2 Q53538428-C5866C80-F7CB-4FA9-9C30-D2A577C29976 Q54974390-0A078C74-6798-44DC-A8E8-186BC82A5935 Q55403230-E6901456-4772-4CFF-9CFB-F506458E5A4F Q55431604-900A56D2-7C02-4AF8-8A88-621F533A0236 Q57105258-6CCE485A-C93E-410A-8FEF-F0D862A3394E Q59128489-93DB15F4-3782-4CB6-9011-E0C4B86CC791

P2860

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Item

http://www.wikidata.org/entity/Q34611626

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu